BioCentury
ARTICLE | Product Development

Perennial pioneer

How Richard Peters plans to keep Genzyme ahead in Orphan diseases

June 8, 2015 7:00 AM UTC

Genzyme Corp. aims to remain a leader in Orphan diseases by adopting clinical innovations from oncology and continuing to engage patients from early research all the way to the market to speed development, approval and reimbursement of new drugs that meet patient needs.

BioCentury recently spoke with Richard Peters, who was named Genzyme's new global head of rare diseases in May after serving as head of global & U.S. medical affairs for the Genzyme Transplant & Oncology Division, and medical officer for Sanofi Global Oncology. ...